secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2026-04-17T23:59:59+00:00
Accession:  0001104659-26-044952
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud

BioXcel Therapeutics issues warrants to purchase 1.35M shares at $0.01 per share under credit amendment
--------------------------------------------------------------------------------

- On April 15, 2026, BioXcel Therapeutics granted lenders warrants to purchase up to 1,353,729 shares of common stock at an exercise price of $0.01 per share.
- The warrants were issued pursuant to the Ninth Amendment to the Credit Agreement and Guaranty, dated April 19, 2022.
- The Company also entered into a Fourth Amended and Restated Registration Rights Agreement with the lenders to register shares underlying the warrants.
- The lenders include entities such as Oaktree-TCDRS Strategic Credit, LLC, Oaktree Specialty Lending Corporation, and others.
- The warrants expire on the seventh anniversary of issuance and were issued in reliance on Section 4(a)(2) of the Securities Act.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926044952/0001104659-26-044952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926044952/tm2612008d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-044952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer